Early Detection Research Network

Last updated

The Early Detection Research Network (EDRN) is a collaboration led by the National Cancer Institute (NCI) focused on the discovery of cancer biomarkers. The effort, started in 2000, includes both principal investigators and associate members from leading research institutions across the United States.

The objectives of EDRN include:

Since 2000, EDRN has established a national infrastructure to support validation of cancer biomarkers through innovative research and technology approaches. EDRN supports validation of some of the most promising proteomic and genomic markers evaluating their results for continued research. The biomarkers must be reliable and repeatable in testing; highly sensitive and specific; quantitative; readily obtained by non-invasive methods; part of the causal pathway for disease; capable of being modulated by the chemopreventive agent; and have high predictive value for clinical disease.

The EDRN is organized to perform research around specific organ sites. Research teams within and outside EDRN are established to develop protocols of study around each of these organ sites. Within the EDRN, collaborations are established so researchers involved in specific organs can work together and study results. These organ groups include breast and gynecologic cancers, colorectal and other gastrointestinal cancers, Lung and upper aerodigestive cancers, prostate and other urologic cancers.

The EDRN also has been a pioneer in the development of a national informatics infrastructure to support cancer biomarker research. By leveraging technology development for planetary science at NASA's Jet Propulsion Laboratory, the EDRN has been able to develop and deploy an infrastructure to support data sharing, knowledge management and collaborate research. The informatics activities within EDRN are led by the Informatics Center at NASA Jet Propulsion Laboratory, Fred Hutchinson Cancer Research Center, and Dartmouth Medical School.


Related Research Articles

Pathology Study of the causes and effects of disease or injury, also how they arise

Pathology is the study of the causes and effects of disease or injury. The word pathology also refers to the study of disease in general, incorporating a wide range of biology research fields and medical practices. However, when used in the context of modern medical treatment, the term is often used in a narrower fashion to refer to processes and tests which fall within the contemporary medical field of "general pathology", an area which includes a number of distinct but inter-related medical specialties that diagnose disease, mostly through analysis of tissue, cell, and body fluid samples. Idiomatically, "a pathology" may also refer to the predicted or actual progression of particular diseases, and the affix pathy is sometimes used to indicate a state of disease in cases of both physical ailment and psychological conditions. A physician practicing pathology is called a pathologist.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).

Biocomplexity Institute of Virginia Tech Research organization for computational biology and related fields

The Biocomplexity Institute of Virginia Tech is a research organization specializing in bioinformatics, computational biology, and systems biology. The Institute has more than 250 personnel, including over 50 tenured and research faculty. Research at the Institute involves collaboration in diverse disciplines such as mathematics, computer science, biology, plant pathology, biochemistry, systems biology, statistics, economics, synthetic biology and medicine. The institute develops -omic and bioinformatic tools and databases that can be applied to the study of human, animal and plant diseases as well as the discovery of new vaccine, drug and diagnostic targets.

MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. It gives a binary result, high-risk or low-risk classification, and helps physicians determine whether or not a patient will benefit from chemotherapy. Women with a low risk result can safely forego chemotherapy without decreasing likelihood of disease free survival. MammaPrint is part of the personalized medicine portfolio marketed by Agendia.

Biomarker discovery is a medical term describing the process by which biomarkers are discovered. Many commonly used blood tests in medicine are biomarkers. There is interest in biomarker discovery on the part of the pharmaceutical industry; blood-test or other biomarkers could serve as intermediate markers of disease in clinical trials, and as possible drug targets.

The cancer Biomedical Informatics Grid (caBIG) was a US government program to develop an open-source, open access information network called caGrid for secure data exchange on cancer research. The initiative was developed by the National Cancer Institute and was maintained by the Center for Biomedical Informatics and Information Technology (CBIIT). In 2011 a report on caBIG raised significant questions about effectiveness and oversight, and its budget and scope were significantly trimmed. In May 2012, the National Cancer Informatics Program (NCIP) was created as caBIG's successor program.

In biomedical contexts, a biomarker, or biological marker, is a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated using blood, urine, or soft tissues to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers are used in many scientific fields.

In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. According to the WHO, the indicator may be chemical, physical, or biological in nature - and the measurement may be functional, physiological, biochemical, cellular, or molecular.

Sensitivity and specificity Statistical measures of the performance of a binary classification test

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence or absence of a condition. Individuals for which the condition is satisfied are considered "positive" and those for which it is not are considered "negative".

Avesthagen Indian biological products company

Avesthagen Limited is an integrated systems biology platform company headquartered in Bangalore, India. It was founded as an academic startup in 1998 by Villoo Morawala-Patell, a Rockefeller Fellow and grantee within NCBS-UAS, Bangalore. Avesthagen started business operations on March 21, 2001 with Series-A round investment led by ICICI Ventures and Tata Industries. Dr.Villoo Morawala Patell, is the Chairperson and Managing Director of Avesthagen Limited.

IIT Research Institute

IIT Research Institute (IITRI), also known historically and interchangeably as IIT Research Center, is a high-technology scientific research organization and applied research laboratory located in Chicago, Illinois. Previously known as the Armour Research Foundation, the IITRI is an independent corporation that operates collaboratively with the Illinois Institute of Technology (IIT) and the U.S. Government.

Rosetta Genomics Ltd. was a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid (microRNA) biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008. The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC); differentiate between adenocarcinoma and peritoneal mesothelioma; and seek to identify the origin of tumors in patients representing cancer of unknown primary (CUP). Using a single microRNA, the highly sensitive, highly specific test for squamous and non-squamous lung cancer has passed the prevalidation phase and has been submitted for approval to the New York State Department of Health Clinical Laboratory Evaluation Program in April 2008.

An imaging biomarker is a biologic feature, or biomarker detectable in an image. In medicine, an imaging biomarker is a feature of an image relevant to a patient's diagnosis. For example, a number of biomarkers are frequently used to determine risk of lung cancer. First, a simple lesion in the lung detected by X-ray, CT, or MRI can lead to the suspicion of a neoplasm. The lesion itself serves as a biomarker, but the minute details of the lesion serve as biomarkers as well, and can collectively be used to assess the risk of neoplasm. Some of the imaging biomarkers used in lung nodule assessment include size, spiculation, calcification, cavitation, location within the lung, rate of growth, and rate of metabolism. Each piece of information from the image represents a probability. Spiculation increases the probability of the lesion being cancer. A slow rate of growth indicates benignity. These variables can be added to the patient's history, physical exam, laboratory tests, and pathology to reach a proposed diagnosis. Imaging biomarkers can be measured using several techniques, such as CT, electroencephalography, magnetoencephalography, and MRI.

DirectHit is a pharmacodiagnostic test used to determine the tumor sensitivity or resistance to drug regimens recommended for the treatment of breast cancer by the National Comprehensive Cancer Network. It is a noninvasive test performed on small amounts of tissue removed during the original surgery lumpectomy, mastectomy, or core biopsy. DirectHit was developed by CCC Diagnostics Inc., a biotechnology company established by former researchers from Johns Hopkins University. DirectHit was launched on 14 January 2010. Currently, it is the only available test for predicting treatment outcomes for anticancer chemotherapy drugs for breast cancer.

Epigenomics AG is a molecular diagnostics company headquartered in Berlin, Germany with a wholly owned subsidiary, Epigenomics Inc. based in Seattle, WA.

Translational bioinformatics (TBI) is an emerging field in the study of health informatics, focused on the convergence of molecular bioinformatics, biostatistics, statistical genetics and clinical informatics. Its focus is on applying informatics methodology to the increasing amount of biomedical and genomic data to formulate knowledge and medical tools, which can be utilized by scientists, clinicians, and patients. Furthermore, it involves applying biomedical research to improve human health through the use of computer-based information system. TBI employs data mining and analyzing biomedical informatics in order to generate clinical knowledge for application. Clinical knowledge includes finding similarities in patient populations, interpreting biological information to suggest therapy treatments and predict health outcomes.

In silico medicine is the application of in silico research to problems involving health and medicine. It is the direct use of computer simulation in the diagnosis, treatment, or prevention of a disease. More specifically, in silico medicine is characterized by modeling, simulation, and visualization of biological and medical processes in computers with the goal of simulating real biological processes in a virtual environment.

Molecular diagnostics Collection of techniques used to analyze biological markers in the genome and proteome

Molecular diagnostics is a collection of techniques used to analyze biological markers in the genome and proteome, and how their cells express their genes as proteins, applying molecular biology to medical testing. In medicine the technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients, and in agricultural biosecurity similarly to monitor crop- and livestock disease, estimate risk, and decide what quarantine measures must be taken.

An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed. The adaptation process generally continues throughout the trial, as prescribed in the trial protocol. Adaptions may include modifications to: dosage, sample size, drug undergoing trial, patient selection criteria and/or "cocktail" mix. In some cases, trials have become an ongoing process that regularly adds and drops therapies and patient groups as more information is gained. Importantly, the trial protocol is set before the trial begins which pre-specifies the adaptation schedule and processes.

Receiver Operating Characteristic Curve Explorer and Tester (ROCCET) is an open-access web server for performing biomarker analysis using ROC curve analyses on metabolomic data sets. ROCCET is designed specifically for performing and assessing a standard binary classification test. ROCCET accepts metabolite data tables, with or without clinical/observational variables, as input and performs extensive biomarker analysis and biomarker identification using these input data. It operates through a menu-based navigation system that allows users to identify or assess those clinical variables and/or metabolites that contain the maximal diagnostic or class-predictive information. ROCCET supports both manual and semi-automated feature selection and is able to automatically generate a variety of mathematical models that maximize the sensitivity and specificity of the biomarker(s) while minimizing the number of biomarkers used in the biomarker model. ROCCET also supports the rigorous assessment of the quality and robustness of newly discovered biomarkers using permutation testing, hold-out testing and cross-validation.